Truist Securities maintains Encompass Health at Buy, raises price target to $156 from $150

What happened

Truist Securities kept its Buy rating on Encompass Health and raised its price target to $156 from $150, a 4.0% increase. The new target implies 18.6% upside from the October 29 close of $131.49.

Confirmed

Global impact / market context

A higher price target signals that an analyst expects more share price gain ahead. For current owners, it is a vote of confidence. For new buyers, the implied 18.6% upside depends on the share price staying near the October 29 close.

Analyst inference

Analyst price targets are one input, not a guarantee. Truist now sees about 18.6% upside from $131.49, up from the prior target. Investors often compare such targets with their own view of the company's earnings and risks.

Analyst inference

What to watch

1. The October 29 close was $131.49, and the $156 target implies 18.6% upside; watch whether the share price moves toward that level. Confirmed
2. Watch for future Truist updates, since a further target change or a rating change away from Buy would alter the outlook described here. Proposed
3. Other analysts' targets and ratings for Encompass Health could differ; a split view would mean the stock's expected upside is less certain than one rating suggests. Analyst inference

Evidence

• Original source link unavailable